Quotient Ltd (NASDAQ:QTNT) – Equities research analysts at Jefferies Financial Group cut their Q3 2019 earnings per share estimates for shares of Quotient in a report released on Monday, November 5th. Jefferies Financial Group analyst B. Couillard now anticipates that the company will earn ($0.41) per share for the quarter, down from their prior forecast of ($0.35). Jefferies Financial Group also issued estimates for Quotient’s Q4 2019 earnings at ($0.39) EPS, FY2019 earnings at ($1.85) EPS, Q1 2020 earnings at ($0.32) EPS, Q4 2020 earnings at ($0.31) EPS and FY2020 earnings at ($1.28) EPS.
Quotient (NASDAQ:QTNT) last posted its earnings results on Monday, November 5th. The company reported ($0.53) EPS for the quarter, missing analysts’ consensus estimates of ($0.36) by ($0.17). The business had revenue of $6.25 million for the quarter, compared to analyst estimates of $5.80 million.
NASDAQ QTNT opened at $6.67 on Thursday. The stock has a market cap of $347.47 million, a price-to-earnings ratio of -3.30 and a beta of 0.45. Quotient has a one year low of $2.78 and a one year high of $9.02.
Several institutional investors have recently modified their holdings of QTNT. The Manufacturers Life Insurance Company grew its position in shares of Quotient by 341.8% in the 1st quarter. The Manufacturers Life Insurance Company now owns 21,820 shares of the company’s stock worth $103,000 after buying an additional 16,881 shares during the last quarter. FNY Investment Advisers LLC purchased a new position in shares of Quotient in the 2nd quarter worth approximately $693,000. West Chester Capital Advisors Inc. purchased a new position in shares of Quotient in the 2nd quarter worth approximately $120,000. Gilder Gagnon Howe & Co. LLC purchased a new position in shares of Quotient in the 2nd quarter worth approximately $1,702,000. Finally, LMR Partners LLP purchased a new position in shares of Quotient in the 2nd quarter worth approximately $519,000. 49.19% of the stock is currently owned by hedge funds and other institutional investors.
Quotient Limited, a commercial-stage diagnostics company, develops, manufactures, and commercializes conventional reagent products used for blood grouping in the transfusion diagnostics market worldwide. The company is developing MosaiQ, a proprietary technology platform, which provides tests for blood grouping and serological disease screening.
Further Reading: Fundamental Analysis and Individual Investors
Receive News & Ratings for Quotient Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quotient and related companies with MarketBeat.com's FREE daily email newsletter.